Aparito

14/10/2024

New paper! 📔 Demonstrating the feasibility of using a smartphone app for home-based video assessments of gait and balance in people living with 📱👟

The could enhance patient engagement and provide more real world data for future trials.

Discover more 👇
https://hubs.li/Q02Sk16Q0

10/10/2024

Excited to announce that Dr. Elin Haf Davies will be speaking on the “Investment for TechBio Companies” panel at TechBio UK!

Learn more and register here 👇
https://hubs.li/Q02SjXTW0

30/09/2024

It's and to mark we revisit GaRDIAN, a patient-led, patient-owned registry for neuronopathic disease (nGD), a rare condition that has a significant impact on patients and caregivers.

nGD has minimal natural history (combined with small patient numbers and huge heterogeneity within the same genotype) so GaRDIAN intends to bridge the many gaps in the understanding of nGD and align with regulatory frameworks on real-world data needs.

Read the paper here 👇
https://hubs.li/Q02Rsy3s0

25/09/2024

On we share our work to digitise the Scale for the Assessment and Rating of Ataxia (SARA) into SARAhome to measure the impact of on patients’ everyday lives. 📱

This approach enabled us to develop a video where daily assessments provide a more meaningful measure of the severity of ataxia than a conventional snapshot visit conducted once a year. 📈

Discover more about SARAhome in our white paper here 📚
https://hubs.li/Q02QLs4P0

12/09/2024

07/09/2024

On , Duchenne UK and Aparito celebrate our decentralised validation study using home-based video assessments to track limb function in patients with Duchenne muscular dystrophy ( ). 📚

DMDhome uses video capture and computer vision analysis to measure limb function in Duchenne muscular dystrophy and the study intends to validate the DMDhome platform to improve the evaluation of new treatments.

Recruitment is now ongoing, offering participants the opportunity to contribute from home in the validation of novel .
Discover more about the study here 👇
https://hubs.li/Q02NMw0h0

30/08/2024

There's only one month left to claim your free ticket to our 10th anniversary! 🎆

🗓️ 15 October 2024
🕛 12:00 until 17:00 BST
📍 The British Museum, London

We'll reveal our agenda and speakers over the coming weeks. 👀

Tickets are available here until 30 September 👇
https://hubs.li/Q02M_Mm20

07/08/2024

Welcome to the team, Tatti.
What job title should we give her? We're thinking Head of Pawsitivity... 🐶

06/08/2024

📗New paper alert! 📗

In "Digital endpoints in clinical trials: emerging themes from a multi-stakeholder Knowledge Exchange event" the authors discuss how digital technologies can enable the decentralisation of .

📚 Background
Digital technologies, such as wearable devices and smartphone applications (apps), can enable the decentralisation of clinical trials by measuring endpoints in people’s chosen locations rather than in traditional clinical settings. Digital endpoints can allow high-frequency and sensitive measurements of health outcomes compared to visit-based endpoints which provide an episodic snapshot of a person’s health. However, there are underexplored challenges in this emerging space that require interdisciplinary and cross-sector collaboration. A multi-stakeholder Knowledge Exchange event was organised to facilitate conversations across silos within this research ecosystem.

👩🏽‍🔬Methods
A survey was sent to an initial list of stakeholders to identify potential discussion topics. Additional stakeholders were identified through iterative discussions on perspectives that needed representation. Co-design meetings with attendees were held to discuss the scope, format and ethos of the event. The event itself featured a cross-disciplinary selection of talks, a panel discussion, small-group discussions facilitated via a rolling seating plan and audience participation via Slido. A transcript was generated from the day, which, together with the output from Slido, provided a record of the day’s discussions. Finally, meetings were held following the event to identify the key challenges for digital endpoints which emerged and reflections and recommendations for dissemination.

Read the paper in full here 👇
https://hubs.li/Q02KbgBs0

29/07/2024

We're exiting from Aparito, a Wrexham-based med-tech business, having achieved an initial return of 2.9x on our £1.2 million equity investment, with the potential to increase to 3.2x.

They have now been acquired by the global pharmaceutical company Eli Lilly and Company.

Since its inception in 2014 through the Bethnal Green Ventures Accelerator, Aparito has been at the forefront of transforming drug development by digitising decentralised clinical trials.

Aparito's journey includes joining Bayer Pharmaceuticals’ G4A health tech accelerator in 2017. We were pleased to make the first of three equity investments in Aparito, totaling £1.2 million, alongside co-investors Bethnal Green Ventures, Wealth Club, and Ascension VC.

Headquartered in Indianapolis, Indiana, Eli Lilly operates in 18 countries and offers medical products worldwide. Aparito is now a valued subsidiary of Eli Lilly and Company. Dr. Davies will continue as Chief Executive, along with all 26 staff members in Wrexham and five in Barcelona. The company will maintain its operations in Wrexham.

Learn more: https://ow.ly/ovX450SKKUj



Eli Lilly and Company . Aparito . Business and Investment - Wrexham County Borough Council . This Is Wrexham . Love Wrexham . Wrexham Small Business Network . Med-Tech Innovation . Business Wales . Business News Wales

29/07/2024

Rydym yn gadael Aparito, busnes technoleg feddygol yn Wrecsam, ar ôl cael elw cychwynnol o 2.9x ar ein buddsoddiad ecwiti o £1.2 miliwn, gyda'r potensial i gynyddu i 3.2x.

Maent bellach wedi'u caffael gan y cwmni fferyllol byd-eang Eli Lilly and Company.

Ers ei sefydlu yn 2014 trwy'r Bethnal Green Ventures Accelerator, mae Aparito wedi bod ar flaen y gad o ran trawsnewid datblygiad cyffuriau trwy ddigideiddio treialon clinigol datganoledig.

Mae taith Aparito yn cynnwys ymuno â chyflymydd technoleg iechyd G4A Bayer Pharmaceuticals yn 2017. Roeddem yn falch o wneud y cyntaf o dri buddsoddiad ecwiti yn Aparito, cyfanswm o £1.2 miliwn, ochr yn ochr â chyd-fuddsoddwyr Bethnal Green Ventures, Wealth Club, ac Ascension VC.

Gyda'i bencadlys yn Indianapolis, Indiana, mae Eli Lilly yn gweithredu mewn 18 o wledydd ac yn cynnig cynhyrchion meddygol ledled y byd. Mae Aparito bellach yn is-gwmni gwerthfawr i Eli Lilly and Company. Bydd Dr. Davies yn parhau fel Prif Weithredwr, ynghyd â phob un o'r 26 aelod o staff yn Wrecsam a phump yn Barcelona. Bydd y cwmni yn cynnal ei weithrediadau yn Wrecsam.

Dysgwch fwy: https://ow.ly/qSl750SM64s



Eli Lilly and Company . Aparito . Business and Investment - Wrexham County Borough Council . This Is Wrexham . Love Wrexham . Wrexham Small Business Network . Med-Tech Innovation . Busnes Cymru . Business News Wales

15/07/2024

Global pharmaceutical player Eli Lilly and Company has acquired Aparito, a Wrexham-based med-tech business founded by Dr. Elin Haf Davies.

We’re now exiting Aparito, with our investment having yielded an initial return of 2.9x on our £1.2 million equity investment, with the potential to increase to 3.2x.

Since its establishment in 2014 as part of the Bethnal Green Ventures Accelerator, Aparito has been at the forefront of accelerating drug development through the digitisation of decentralised clinical trials.

Aparito joined Bayer Pharmaceuticals’ G4A health tech accelerator in 2017. We made the first of three equity investments in Aparito, totaling £1.2 million, alongside co-investors Bethnal Green Ventures, Wealth Club, and Ascension VC.

Headquartered in Indianapolis, Indiana, Eli Lilly operates in 18 countries and sells medical products worldwide. Aparito is now a wholly-owned subsidiary of Eli Lilly and Company. Dr. Davies will continue as Chief Executive, along with all 26 staff in Wrexham and five in Barcelona. The company will maintain its operations in Wrexham.

Discover more: https://ow.ly/PnKP50SBcWa



Eli Lilly and Company . Aparito . Business and Investment - Wrexham County Borough Council . This Is Wrexham . Love Wrexham . Wrexham Small Business Network . Med-Tech Innovation . Business Wales . Business News Wales

12/07/2024

Exciting news from Brussels this week as the project officially launches! 🎉
This groundbreaking project is set to revolutionize healthcare services by developing a 5G-powered platform that will connect P4-based healthcare services (predictive, preventive, personalized, participatory) across various specialties. 👩‍💻

Intending to improve profitability and efficiency in healthcare, the 5G4PHealth project brings together a diverse consortium of 16 entities, including tech and healthcare providers, researchers, academia, clinicians, and cybersecurity experts, from six European countries. 🌍

We're excited to see the collaboration and innovation that will come from this project! 🏥

11/07/2024

A Welsh med-tech business has been acquired by global pharmaceutical company Eli Lilly and Company.

04/07/2024

Merci beaucoup, Paris. 🇫🇷 We met with our partners where our first patient joined for lunch and made cake for us 🍰
engagement with the project has been encouraging with over 80% on adherence and >60% of videos passing quality control!

02/07/2024

Aparito is now ISO/IEC 27001:2022 certified! 🥳
After congratulating our wonderful team, you may ask, what’s changed from ISO/IEC 27001:2013, and why does it matter?

🛡️With cybercrime on the rise and newer threats constantly emerging, managing cyber risks can seem difficult. ISO/IEC 27001:2022 helps us become risk-aware and proactively identify and address weaknesses, thereby strengthening our systems.

🔒 An information security management system implemented as per this standard is a tool for risk management, cyber-resilience, and operational excellence.

⚛️ ISO/IEC 27001:2022 promotes a holistic approach to information security: vetting people, policies, and technology.

🎛️ It increases senior leadership involvement in information security management, ensuring that information security and data integrity are front and centre in the strategic direction of Aparito and our platform product roadmap.

Atom5™ is built with integrated security and data quality. This certification further strengthens Atom5™ and aligns with Aparito’s founding principles of privacy by design.

24/06/2024

Our latest webinar is now available on demand! 🦋

In "Facilitating Patient Preference in Rare Epilepsy Studies", we asked our panel of experts from epihunter Syngap Research Fund - SRF and Fundación Síndrome de Dravet how we should capture data to balance the needs of regulators seeking real-world data and the patients and caregivers who want to measure what matters to them.

View the recording here 👇
https://hubs.li/Q02C_gK30

23/06/2024

On , we revisit our publication, "A patient-centred and multi-stakeholder co-designed observational prospective study protocol: Example of the adolescent experience of treatment for X-linked hypophosphataemia ( )", a diverse team of expert physicians, researchers, technology specialists, patients, and caregivers came together to co-design a prospective observational study on hashtag , a rare disease affecting adolescents.

Collaboration and patient engagement were key in ensuring the study's success. The research team worked together to identify relevant research questions, select appropriate outcome measures, and assess the feasibility and acceptability of data collection methods.

By involving patients, caregivers, and clinicians in the study design, the researchers ensured a patient-centric approach and gained valuable insights into the lived experience of the disease and its treatments.

This patient-centric approach allowed for flexible research methods and a deep understanding of the disease, which is especially important for rare diseases where knowledge may be limited.

Read the paper here 👇
https://hubs.li/Q02CPz530